Video

Dr. Matthew Katz on Borderline Resectable Pancreatic Cancer

Matthew H.G. Katz, MD, from the MD Anderson Cancer Center, discusses borderline resectable pancreatic ductal adenocarcinoma, a newer stage of pancreatic cancer introduced by the NCCN in 2003.

Matthew H.G. Katz, MD, assistant professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses borderline resectable pancreatic ductal adenocarcinoma (PDAC), a newer stage of pancreatic cancer introduced by the NCCN in 2003.

Katz describes patients with borderline resectable PDAC as a group of patients with localized pancreatic cancer who are between those who are eligible for surgery and those who are not.

This group of patients is particularly important, Katz explains, because they have traditionally been added to the unresectable stage. The standard treatment for unresectable pancreatic cancer is palliative care with an average survival of 12-14 months, adds Katz. However, patients with borderline resectable PDAC may undergo neoadjuvant treatment, which makes surgery feasible and improves survival.

Once undergoing neoadjuvant therapy and surgery, the borderline subgroup may experience an overall survival along the same lines as those who have resectable tumors.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity